High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
Katharine Louise LewisLasse Hjort Kyneb JakobsenDiego R VillaKarin E SmedbyKerry Joane SavageToby Andrew EyreKate CwynarskiMark J BishtonChristopher Paul FoxEliza A HawkesMatthew John MaurerTarec C El-GalalyChan Yoon Y Cheahnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
In this large study, high-risk patients receiving HD-MTX had a 7.2% 2-year risk of CNS progression, consistent with the progression risk in previously reported high-risk cohorts. Use of HD-MTX was not associated with a clinically meaningful reduction in risk of CNS progression.